{
    "title": "Eli Lilly and Company. Q3 FY23 Income Statement",
    "unit": "M",
    "values": [
        {
            "id": "DiabetesRevenue",
            "v": 4720,
            "color": "blue",
            "name": "Diabetes Revenue"
        },
        {
            "id": "OncologyRevenue",
            "v": 1747,
            "color": "blue",
            "name": "Oncology Revenue"
        },
        {
            "id": "ImmunologyRevenue",
            "v": 987,
            "color": "blue",
            "name": "Immunology Revenue"
        },
        {
            "id": "NeuroscienceRevenue",
            "v": 1768.1,
            "color": "blue",
            "name": "Neuroscience Revenue"
        },
        {
            "id": "OthersRevenue",
            "v": 276,
            "color": "blue",
            "name": "Others Revenue"
        },
        {
            "id": "TotalRevenue",
            "v": 9499,
            "color": "blue",
            "name": "Total Revenue"
        },
        {
            "id": "CostOfRevenue",
            "v": 1860,
            "color": "red",
            "name": "Cost of Revenue"
        },
        {
            "id": "GrossProfit",
            "v": 7639,
            "color": "green",
            "name": "Gross Profit",
            "sort": -1
        },
        {
            "id": "OperatingExpense",
            "v": 7211,
            "color": "red",
            "name": "Operating Expense"
        },
        {
            "id": "RDExpense",
            "v": 2409,
            "color": "red",
            "name": "R&D Expense"
        },
        {
            "id": "MarketingSellingAdminExpense",
            "v": 1804,
            "color": "red",
            "name": "Marketing, Selling & Admin "
        },
        {
            "id": "AcquiredInProcessRD",
            "v": 2975,
            "color": "red",
            "name": "Acquired in-process R&D"
        },
        {
            "id": "OtherExpense",
            "v": 23,
            "color": "red",
            "name": "Other Expense"
        },
        {
            "id": "OperatingProfit",
            "v": 427,
            "color": "green",
            "name": "Operating Profit",
            "sort": -1
        },
        {
            "id": "Tax",
            "v": 485,
            "color": "red",
            "name": "Tax"
        },
        {
            "id": "NetLoss",
            "v": -57,
            "color": "red",
            "name": "Net Loss"
        }
    ],
    "link": [
        {
            "from": "DiabetesRevenue",
            "to": "TotalRevenue"
        },
        {
            "from": "OncologyRevenue",
            "to": "TotalRevenue"
        },
        {
            "from": "ImmunologyRevenue",
            "to": "TotalRevenue"
        },
        {
            "from": "NeuroscienceRevenue",
            "to": "TotalRevenue"
        },
        {
            "from": "OthersRevenue",
            "to": "TotalRevenue"
        },
        {
            "from": "TotalRevenue",
            "to": "CostOfRevenue"
        },
        {
            "from": "TotalRevenue",
            "to": "GrossProfit"
        },
        {
            "from": "GrossProfit",
            "to": "OperatingExpense"
        },
        {
            "from": "OperatingExpense",
            "to": "RDExpense"
        },
        {
            "from": "OperatingExpense",
            "to": "MarketingSellingAdminExpense"
        },
        {
            "from": "OperatingExpense",
            "to": "AcquiredInProcessRD"
        },
        {
            "from": "OperatingExpense",
            "to": "OtherExpense"
        },
        {
            "from": "GrossProfit",
            "to": "OperatingProfit"
        },
        {
            "from": "OperatingProfit",
            "to": "Tax"
        },
        {
            "from": "NetLoss",
            "to": "Tax"
        }
    ]
}